系统性红斑狼疮的达标治疗现状

Current Status of Treat-to-Target Therapy in Systemic Lupus Erythematosus

摘要: 达标治疗(Treat-to-target, T2T)的概念改善了糖尿病、高血压和类风湿关节炎患者的预后。这种治疗策略包括选择一个明确的、相关的目标，采取治疗步骤，评估目标是否已经实现，如果没有实现就采取行动。T2T原则已被系统性红斑狼疮(systemic lupus erythematosus, SLE)专家所接受，但需要可实现的结果，以及治疗方案，才能使这种方法在实践中成为可能。目前SLE的治疗方案有限，迫切需要更有效、更安全的治疗方法。幸运的是，SLE的临床试验活动，包括生物和小分子药物，已经看到了令人鼓舞的结果。因此，随着此类治疗的预期出现，在可预见的未来，很可能会出现足够多样化的SLE治疗方法，从而使T2T在SLE患者的护理中得到常规实施。

Abstract: Treat-to-target therapy (T2T) has improved outcomes in patients with diabetes, hypertension, and rheumatoid arthritis. This treatment strategy involves selecting a clear, relevant goal, taking ther-apeutic steps, assessing whether the goal has been achieved, and taking action if not. The T2T prin-ciple is accepted by experts in systemic lupus erythematosus (systemic lupus erythematosus), but measurable and achievable outcomes, as well as treatment options, are needed to make this ap-proach possible in practice. Current treatment options for SLE are limited and more effective and safer treatments are urgently needed. Fortunately, clinical trial activities in SLE, including biologi-cal and small molecule drugs, have seen encouraging results. Thus, with the expected emergence of such treatments, it is likely that enough diverse treatments for SLE will emerge in the foreseeable future so that T2T is routinely implemented in the care of patients with SLE.